Bookmarks
CASPS: A Phase II trial of Cediranib in ASPS patients
Population Size
Not reported
Years
2010
Associated BioSamples
Availability to be confirmed
Geographic coverage
United Kingdom
England
Lead time
Other
Summary
Collection of samples and data across the following diseases: Malignant neoplasm of connective tissue (disorder)
Documentation
CASPS is a two-arm, randomised, double-blind, placebo-controlled, Phase II trial of cediranib in ASPS patients. The primary objective is to evaluate the efficacy of cediranib by measuring the percentage change in the sum of target marker lesion diameters from randomisation to week 24 compared to placebo. Secondary objectives include: progression-free survival, overall survival and safety and tolerability of cediranib in ASPS patients. Tissue markers of tumour response, circulating markers of angiogenesis, and changes in circulating endothelial cells/precursor cells in response to cediranib will be explored. Thirty six patients with progressive, metastatic, histologically confirmed ASPS will be recruited. Patients will be randomised to 24 weeks of blinded cediranib or placebo, after which treatment will be unblinded and all patients offered open-label cediranib until objective disease progression, or death if sooner.
Dataset type
Health and disease
Dataset sub-type
Not applicable
Keywords
Provenance
Image contrast
Not stated
Biological sample availability
Availability to be confirmed
Details
Publishing frequency
Other
Version
1.0.0
Modified
08/10/2024
Citation Requirements
In Progress
Coverage
Start date
01/01/2010
Time lag
Variable
Geographic coverage
United Kingdom, England
Accessibility
Language
en
Controlled vocabulary
LOCAL
Format
In Progress
Data Access Request
Dataset pipeline status
Not available
Access rights
Please contact the publisher using Contact Point details provided
Time to dataset access
Other
Access request cost
Not specified
Access method category
Varies based on project
Data Controller
The Institute of Cancer Research